Contents

1 Introduction 1
Historical Note 1
Suggested Readings 5

2 Indication, Collection, and Laboratory Processing of Cytologic Samples 7
General 7
Methods of Specimen Collection 8
Voided Urine 8
Catheterized Urine 9
Direct Sampling techniques 9
Ileal Bladder Urine 10
Laboratory Processing of Urinary Specimens 10
Liquid-Based Processing Techniques 10
SurePath 10
ThinPrep 14
Residual LBP Specimen 15
Suggested Readings 15

3 The Cellular and Acellular Components of the Urinary Sediment 17
Normal Lower Urinary Tract 17
Anatomy 17
Normal Urothelium (Transitional Epithelium) and Its Cells 18
Histology and Ultrastructure 18
Ultrastructure of the Umbrella Cells 19
Variants of Normal Urothelium 21
Cells Derived from Normal Urothelium 21
Other Benign Cells 28
Squamous Cells 28
Blood Cells 31
Erythrocytes 31
Noncellular Components of Urinary Sediment 32
Crystals 32
Suggested Readings 35

4 The Cytologic Makeup of the Urinary Sediment According to the Collection Technique 37
Introduction 37
Cytologic Makeup of the Sediment of Normal Voided Urine 37
Cell Preservation in Voided Urine 40
Cytologic Makeup of Bladder Washings 40
Cytologic Makeup of Normal Retrograde Catheterization Specimens 42
Cytologic Makeup of Smears Obtained by Brushing 43
Cytologic Makeup of Ileal Bladder Urine 44
Suggested Readings 45

5 Cytologic Manifestations of Benign Disorders Affecting Cells of the Lower Urinary Tract 47
Inflammatory Disorders 47
Bacterial Agents 47
Pyelonephrirtis 48
Cystitis 48
Hunner's Ulcer (Interstitial Cystitis) 49
Inflammatory Pseudopolyp 49
Eosinophilic Cystitis (Eosinophilic Granuloma) 50
Follicular Cystitis 50
Papillary Hyperplasia 50
Cystitis Cystica and Cystitis Glandularis 51
Nephrogenic Metaplasia (Adenoma) 52
Actinomyces and Norcardia 53
Tuberculosis 53
Fungal Agents 54
Viral Infections 55
Human Polyomavirus (Decoy Cells) 55
Herpes Simplex Virus 59
Human Papillomavirus 60
Cytomegalovirus 60
Cellular Inclusions Not Due to Viral Agents 61
Nonspecific Cytoplasmic Eosinophilic Inclusions (Melamed-Wolinska Bodies) 61
Parasites 62
Trematodes: Schistosoma haematobium 62
Other Parasites 62
Lithiasis 63
Leukoplakia 63
Effect of Drugs 66
Intravesically Administered Drugs 66
Systemically Administered Drugs 66
Cyclophosphamide (Cytoxan, Endoxan) 66
Busulfan (Myleran) 68
Effects of Radiotherapy 68
Urinary Cytology in Bone Marrow Transplant Recipients 68
Monitoring of Renal Transplant Patients 68

Rare Benign Conditions 69
Malakoplakia 69
Benign Giant Cells in Multiple Myeloma 70
Suggested Readings 70

6 Tumors and Related Conditions of the Bladder and Lower Urinary Tract 73
Non-neoplastic Changes 73
Urothelial Hyperplasia 73
Inverted Papilloma 74
Tumors 76
Epidemiology 76
Histologic Classification of Tumors of the Bladder, Renal Pelves, and Ureters 76
Two Pathways of Bladder Tumors 77
Low-Grade Papillary Urothelial Tumors with no/Minimal Nuclear Atypia 78
Low-Grade Papillary Urothelial Carcinoma 78
Cytologic Recognition of Low-Grade Tumors in Urinary Sediment 79
High-Grade Urothelial Tumors 80
High-Grade Papillary Carcinoma 80
Nonpapillary Urothelial Tumors 82
Invasive Urothelial Carcinomas 85
Histologic Patterns 85
Grading 85
Staging 87
Flat Carcinoma In Situ 87
Clinical Presentation 88
Histology 90
Cytologic Recognition of High-Grade Urothelial Tumors in Urinary Sediment 91
Histologic Variants of Urothelial Carcinoma 96
Squamous (Keratinizing) Carcinoma 96
Adenocarcinoma and Its Variants 96
Small Cell (Oat Cell) Carcinomas 99
Metastatic Tumors 100
Carcinoma and Precancerous States of the Uterine Cervix 100
Other Carcinomas of the Female Genital Tract 101
Prostatic Carcinoma 102
Carcinomas of Colon and Rectum 102
Carcinoma of Renal Cell Origin 102
Metastatic Carcinomas from Distant Sites 103
Other Metastatic Tumors 103
Cytologic Monitoring of Patients Treated for Tumors of Lower Urinary Tract 104
Reporting of Cytologic Findings 105
Suggested Readings 106

7 Urine-Based Assays Complementing Cytologic Examination in the Detection of Urothelial Neoplasm 109
Introduction 109
US FDA-Approved Markers 109
Bladder Tumor Antigen (BTA) 109
Nuclear Matrix Protein 22 (NMP22) 110
Fibrin–Fibrinogen Degradation Product (FDP) 111

ImmunoCyt 111
UroVysion 112
Potential Markers in Earlier Phases of Clinical Development 113
Bladder Cancer Antigen-4 (BLCA-4) 113
Survivin 114
UBC Tests 114
CYFRA 21-1 114
Hyaluronic Acid (HA)-Hyaluronidase (HAase) 115
Telomerase 115
Quanticyt 115
Fibroblast Growth Factor Receptor 3 (FGFR3) 116
Mucin 7 (MUC7) 116
VEGF 116
Markers Detected by Immunocytochemistry 117
CKs 117
p53 117
Ki-67 118
p16 118
Epidermal Growth Factor Receptor (EGFR) 118
E-Cadherin 118
Comparison Between Urine Cytology and FDA-Approved Markers 119
Conclusion 120
References 120

Index 123

http://www.springer.com/978-1-4614-2055-2

Koss's Cytology of the Urinary Tract with Histopathologic Correlations

Koss, MD, FCRP, L.G.; Hoda, R.S.

2012, XVI, 125 p., Hardcover
ISBN: 978-1-4614-2055-2